BALTIMORE, April 28 /PRNewswire/ -- Lupin Pharmaceuticals, Inc. announced today the launch of Suprax(R) 400mg Tablets (Cefixime USP) in the US.
This line extension further extends the brand franchise of Lupin's flagship anti-infective brand Suprax(R) (Cefixime for oral suspension 100mg/5ml and 200mg/5ml).
Suprax(R) 400mg Tablets will help Lupin to further increase its share of the $450 Million antibiotic market for the treatment of urinary tract infections. It will also extend use of Suprax(R) to the patient population of children of the age of 12 yrs and older.
"Suprax(R) 400mg Tablets offers an additional value proposition to pediatricians by covering adolescent and teenage patient population. The incidence of urinary tract infections is high in children and pediatricians are the 5th largest specialty prescribing antibiotics for this indication. I expect Suprax(R) 400mg Tablets to add substantial value to the Suprax franchise," said Vinita Gupta, President, LPI.
Suprax(R) 400mg Tablets will be promoted by a 60 strong specialty pediatric sales force. Lupin is also evaluating additional options of reaching out to other specialty doctors. Its efforts will be supplemented by innovative promotional campaigns.
The Suprax(R) brand basket now includes Suprax(R) (Cefixime for oral suspension 100mg/5ml and 200mg/5ml and Suprax(R) 400mg Tablets (Cefixime USP).
About Lupin
Headquartered in Mumbai, Lupin Ltd. is a leading pharmaceutical company with a strong research focus. Lupin Limited develops, manufactures and markets a wide range of quality, affordable generic and branded generic formulations and APIs for the developed and the developing markets of the world. The company has secured global leadership position in Anti-TB and Cephalosporins and has a significant presence in the areas of Cardiovasculars (prils and statins), Diabetology, Asthma and NSAIDS. Twelve of Lupin's facilities have been inspected and approved by the U.S. Food & Drug Administration.
The Company's R&D endeavors have resulted in significant progress in its NCE program. The Company's foray into Drug Delivery Systems has resulted in the development of platform technologies that are being used to develop value added generic pharmaceuticals. Currently positioned amongst the top six pharmaceutical companies of India, the Company is committed to achieve sustainable earnings and growth for all its stakeholders.
For the nine months ended December 2007, the Company's consolidated Revenues and Profit after Tax were US $505 million and US $54 million respectively. Please visit http://www.lupinworld.com for more information about Lupin Ltd.
Lupin Pharmaceuticals, Inc. is the U.S. wholly owned subsidiary of Lupin Limited, which is among the top five Pharmaceutical companies in India. Through its sales and marketing headquarters in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. is dedicated to delivering high-quality, affordable generic medicines trusted by healthcare professionals and patients across geographies. For more information, visit http://www.lupinpharmaceuticals.com.
Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act of 1995:
This release contains forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Many of these risks, uncertainties and other factors include failure of clinical trials, delays in development, registration and product approvals, changes in the competitive environment, increased government control over pricing, fluctuations in the capital and foreign exchange markets and the ability to maintain patent and other intellectual property protection. The information presented in this release represents management's expectations and intentions as of this date. Lupin expressly disavows any obligation to update the information presented in this release.
SOURCE Lupin Pharmaceuticals, Inc.
